Oncolytics Biotech Files 6-K Report
Ticker: ONCY · Form: 6-K · Filed: Dec 23, 2024 · CIK: 1129928
Sentiment: neutral
Topics: foreign-issuer, regulatory-filing, pharmaceutical
Related Tickers: ONC
TL;DR
ONCOLYTICS BIOTECH (ONC) filed a 6-K, standard foreign issuer report.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on December 23, 2024, reporting as a foreign private issuer. The company is based in Calgary, Alberta, Canada, and operates in the Pharmaceutical Preparations sector. This filing is for the month of December 2024 and is submitted under the 1934 Securities Exchange Act.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Oncolytics Biotech Inc.'s status as a foreign private issuer.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain new material financial or operational information.
Key Players & Entities
- ONCOLYTICS BIOTECH INC (company) — Registrant
- 20241223 (date) — Filing Date
- 001-38512 (other) — SEC File Number
- Calgary, Alberta, Canada (location) — Company Headquarters
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K filing is a report of foreign private issuers required to be filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, typically to provide information that the issuer makes or is required to make public in its home country or to send or make public to its security holders.
When was this specific Form 6-K filed?
This Form 6-K was filed on December 23, 2024.
What is the primary business of Oncolytics Biotech Inc. according to the filing?
Oncolytics Biotech Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Does Oncolytics Biotech Inc. file an annual report under Form 20-F or 40-F?
According to the filing, Oncolytics Biotech Inc. indicates it files or will file annual reports under cover of Form 20-F.
Where is Oncolytics Biotech Inc. located?
Oncolytics Biotech Inc. is located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2024-12-23 13:14:12
Filing Documents
- form6krecapandpreview.htm (6-K) — 18KB
- oncyrecapandpreview.htm (EX-99.1) — 34KB
- 0001129928-24-000077.txt ( ) — 53KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date December 23, 2024 Kirk Look Chief Financial Officer